| Trial ID: | L2397 |
| Source ID: | NCT00189774
|
| Associated Drug: |
Nateglinide
|
| Title: |
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|Diabetes Mellitus, Type II
|
| Interventions: |
DRUG: nateglinide
|
| Outcome Measures: |
|
| Sponsor/Collaborators: |
Sponsor: Astellas Pharma Inc | Collaborators: Ajinomoto USA, INC.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2008-03-13
|
| Locations: |
Chubu region, Japan|Chugoku region, Japan|Hokkaido region, Japan|Kanto region, Japan|Kinki region, Japan|Kyushu region, Japan|Tohoku region, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00189774
|
